en.Wedoany.com Reported - Scality and Biomemory announced a strategic partnership on June 2, 2026, in San Francisco and Boston to accelerate the development and enterprise-level integration of DNA-based cold archive storage technology. Scality is a data infrastructure software provider for large-scale storage in the AI era, and Biomemory is a pioneer in industrial-grade DNA data storage systems. The two companies plan to jointly promote DNA storage as a viable, ultra-secure, and long-lasting archive tier within modern object storage environments, complementing rather than replacing existing flash, disk, and tape infrastructure. Scality CEO Jerome Lecat has joined the Biomemory board of directors.
This collaboration aims to combine Scality's software-defined S3 object storage platform with Biomemory's data center-oriented DNA storage system. Scality's platform scales and optimizes across multiple storage media types; Biomemory's DNA storage system is designed with enterprise-grade metrics and a modular architecture. The focus is on integrating DNA storage as a new ultra-secure cold archive tier into Scality-managed storage environments, including its autonomous data infrastructure solution, Scality ADI. The integration roadmap will be jointly developed by the two companies in the coming months.
DNA data storage is transitioning from scientific research to commercial application, emerging as an archive storage solution optimized for ultra-long lifespan and minimal operational requirements. This new tier is particularly suitable for data that needs to be preserved for decades, requiring almost no media refresh and consuming zero standby power. Its core value proposition applies to "store forever, rarely access" scenarios, which demand strict data integrity and ultra-longevity. Key applications include national archives, scientific and genomic data repositories, media and entertainment preservation, regulated financial and medical records, and sovereign or defense workloads. The most urgent demand is expected from organizations that need to preserve high-value data over decades, where loss, corruption, or unreadability could have severe financial, legal, operational, or social consequences.
Biomemory recently acquired assets from DNA pioneer Catalog Technologies, strengthening its foundation and accelerating market readiness. This move marks a decisive step for Biomemory in advancing DNA data storage from the lab to industrialized IT solutions.
Scality CEO Jerome Lecat stated that the future of data storage consists of a spectrum of storage qualities, each optimized for the needs of the data being preserved. DNA storage represents the logical pinnacle of this spectrum: a cold archive tier with density, security immutability, and ultra-longevity that traditional media cannot match. He noted that the partnership with Biomemory is a strategic investment in owning this future, and bringing DNA into the Scality ecosystem ensures that its customers—including the world's most demanding enterprises, governments, and service providers—can leverage it when it matures. As a member of the Biomemory board, he is personally committed to helping accelerate the industry's progress.
The strategic logic of the partnership lies in expanding existing capabilities for managing long-term data archive strategies, intelligent tiering, and secure, cyber-resilient data chain of custody. As the technology matures, Scality is positioned to act as a large-scale control plane around Biomemory's DNA storage, elevating its CORE5 cyber-resilience framework to new levels of secure data storage.
Biomemory CEO Erfan Arwani stated that Biomemory is building DNA storage at enterprise scale and with enterprise expectations—as a modular, data center-ready archive system, not a lab curiosity. To achieve this vision, they need to partner with software providers who understand the full stack, how data moves, how policies are enforced, how resilience is maintained across tiers, and how enterprises manage the lifecycle of their most valuable assets. He considers Scality an ideal partner, whose hardware-aware, software-defined architecture is precisely the control plane needed for DNA storage to realize its potential in production environments. Jerome's addition to the Biomemory board brings strategic alignment and operational experience in scaling storage platforms globally.
Enterprises, government agencies, and service providers seeking to future-proof their long-term data retention strategies can visit www.scality.com for Scality's multi-tier, cyber-resilient storage solutions, and www.biomemory.com for Biomemory's DNA-based cold archive storage solutions. As the partnership progresses, updates on joint integration milestones, customer programs, and technical specifications will be released gradually.
About Scality. Scality builds data infrastructure software for enterprise AI, cyber resilience, and sovereign control, supporting scales from multi-petabytes to exabytes. Its platform uses media-aware lifecycle management driven by human-approved policies to match the right storage media, performance, protection, and cost for each workload and data phase, while AI-driven autonomous operations reduce administrative burden. Based on CORE5 cyber resilience and open-source code principles, Scality ADI, ARTESCA, and RING help the world's most demanding enterprises and government organizations drive AI initiatives, defend critical data, and build infrastructure that lasts for decades. Scality is recognized as a Leader by Gartner and is the foundation for AI to remember, learn, and think.
About Biomemory. Founded in 2021, Biomemory is built on years of research from Sorbonne University and the French National Centre for Scientific Research (CNRS) national laboratories. The company is an innovator and market player at the intersection of biotechnology and information technology, developing IT-oriented data storage and cybersecurity solutions using DNA as a storage medium. Its solutions are engineered and industrialized to ensure data preservation and readability for up to 150 years. Biomemory is committed to environmental sustainability, and its technology provides a path to cost-effective, energy-efficient large-scale cold storage. Its vision is to serve customers of all sizes, from kilobytes to exabytes, requiring long-term data storage and computing. Biomemory is headquartered in Paris, France, with an R&D and production center in Boston, USA.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
